Ziprasidone

What is ziprasidone?

The treatment of bipolar disorder is complex due to the presence of varying configurations of symptoms in patients. The primary treatments for bipolar disorder are pharmacological, and often involve antipsychotic drugs such as the second-generation antipsychotic, ziprasidone.

What is the evidence for ziprasidone as treatment for bipolar disorder?

Symptoms

Moderate quality evidence suggests small to medium-sized effects of better improvement in acute mania symptoms with ziprasidone than with placebo or topiramate, although there was better improvement in mania symptoms with tamoxefin than with ziprasidone.

Moderate quality evidence suggests no differences in depression symptoms, response or remission between low (40-80 mg) and high (120-160 mg) dose ziprasidone.

Moderate quality evidence suggests greater improvement in clinical global impression, depression symptoms, response to treatment, and remission with lurasidone than with ziprasidone.

Side effects

Compared to placebo, moderate quality evidence suggests an increased risk of more prolactin, hyperkinesia, akathisia, muscle weakness, somnolance and sedation with ziprasidone, with no differences in insomnia, agitation or weight gain.

Moderate to low quality evidence suggests lower risk of switching to mania with ziprasidone than with aripiprazole or lamotrigine. There are no differences in rates of switching to depression between ziprasidone and haloperidol.

Moderate quality evidence suggests more somnolence with ziprasidone than with lurasidone.

April 2019

Last updated at: 5:39 am, 2nd April 2019
To view documentation related to this topic download the files below
Fact Sheet Technical Commentary

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.